Investor Relations > details

rhNRG-1 was Approved to Take Phase II Clinical Trial in US


Zensun spent two years on organizing and analysis of our data sets including mechanistic studies, preclinical study, Chinese phase I and II study and Australian phase II clinical study. In the middle of this May, Zensun submitted all these data sets to FDA.

After a critical review of Zensun’s data, FDA approved US phase II clinical trial of rhNRG-1 by skipping phase I study recently. 

rhNRG-1 is not only the first innovative drug approved to take clinical study in US, but a potential block buster drug in global market which will benefit many millions of heart failure sufferers world-wide.